Download PDF
Thromb Haemost 1991; 65(02): 169-173
DOI: 10.1055/s-0038-1647478
Original Article
Schattauer GmbH Stuttgart

Purified Factor XII Has a Higher Specific Activity than the Parent Molecule in Plasma

Walter A Wuillemin
The Central Hematology Laboratory, University of Bern, Inselspital, Bern, Switzerland
,
Miha Furlan
The Central Hematology Laboratory, University of Bern, Inselspital, Bern, Switzerland
,
Isabella Huber
The Central Hematology Laboratory, University of Bern, Inselspital, Bern, Switzerland
,
Bernhard Lämmle
The Central Hematology Laboratory, University of Bern, Inselspital, Bern, Switzerland
› Author Affiliations
Further Information

Publication History

Received: 08 May 1990

Accepted after revision 04 October 1990

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The specific clot promoting activity of factor XII (F XII) in plasma samples from 50 healthy adults was between 30 and 48 U/ mg, whereas the specific activity of purified F XII ranged from 55 to 66 U/mg. This difference was neither due to partial proteolytic activation during purification of F XII nor to the influence of plasma protease inhibitors. Purified F XII showed normal size and charge, as demonstrated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and isoelectric focusing, respectively. The increase of the specific F XII activity during the purification process mainly occurred after anion exchange chromatography on DEAE-Sephadex and after the final gel filtration step. Upon dextran sulfate activation, proteolytic cleavage of F XII and generation of kallikrein-like amidolytic activity was faster in F XII deficient plasma containing purified F XII than in F XII deficient plasma containing a corresponding amount of pooled normal plasma (NHP). The binding to kaolin was similar for both, purified F XII and plasma F XII.

In conclusion, purification alters the properties of F XII in an unknown way, resulting in an increased specific clot promoting activity.

 

  • REFERENCES

  • 1 Cochrane CG, Griffin JH. The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 1982; 33: 241-306
    PubMedGoogle Scholar
  • 2 Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15
    PubMedGoogle Scholar
  • 3 Tans G, Rosing J. Structural and functional characterization of factor XII. Semin Thromb Hemostas 1987; 13: 1-14
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Griffin JH, Cochrane CG. Recent advances in the understanding of contact activation reactions. Semin Thromb Hemostas 1979; 5: 254-273
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Colman RW. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 1984; 73: 1249-1253
    CrossrefPubMedGoogle Scholar
  • 6 Bouma BN, Miles LA, Beretta G, Griffin JH. Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry 1980; 19: 1151-1160
    CrossrefPubMedGoogle Scholar
  • 7 Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-1175
    PubMedGoogle Scholar
  • 8 Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci (USA) 1978; 75: 1998-2002
    CrossrefPubMedGoogle Scholar
  • 9 Ratnoff OD, Saito H. Amidolytic properties of single-chain activated Hageman factor. Proc Natl Acad Sci (USA) 1979; 76: 1461-1463
    CrossrefPubMedGoogle Scholar
  • 10 Saito H, Ratnoff OD, Donaldson VH. Defective activation of clotting, fibrinolytic, and permeability-enhancing system in human Fletcher trait plasma. Circ Res 1974; 34: 641-651
    CrossrefPubMedGoogle Scholar
  • 11 Griffin JH, Cochrane CG. Human factor XII (Hageman factor). Methods Enzymol 1976; 45: 56-65
    PubMedGoogle Scholar
  • 12 Fujikawa K, Davie EW. Human factor XII (Hageman factor). Methods Enzyinol 1981; 80: 198-211
    PubMedGoogle Scholar
  • 13 Saito H, Ratnoff OD, Pensky J. Radioimmunoassay of human Hageman factor (factor XII). J Lab Clin Med 1976; 88: 506-514
    PubMedGoogle Scholar
  • 14 Saito H, Scialla SJ. Isolation and properties of an abnormal Hageman factor (factor XII) molecule in a cross-reacting material-positive Hageman trait plasma. J Clin Invest 1981; 68: 1028-1035
    CrossrefPubMedGoogle Scholar
  • 15 Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zuercher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital F XII deficiency. A study on 74 subjects from 14 Swiss families. Thromb Haemostas 1991; 65: 117-121
    PubMedGoogle Scholar
  • 16 McConahey PJ, Dixon FJ. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy 1966; 29: 185-189
    CrossrefPubMedGoogle Scholar
  • 17 Lowry OH, Rosebrough NJ, Faar AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 18 Wuillemin WA, Furlan M, Lammle B. A quantitative dot immunobinding assay for coagulation factor XII in plasma. J Immunol Methods 1990; 130: 133-140
    CrossrefPubMedGoogle Scholar
  • 19 Lammle B, Berrettini M, Griffin JH. Enhanced specificity of immunoblotting using radiolabeled antigen overlay: studies of blood coagulation factor XII and prekallikrein in plasma. Anal Biochem 1986; 156: 118-125
    CrossrefPubMedGoogle Scholar
  • 20 Righetti P, Drysdale JW. Isoelectric focusing in polyacrylamide gels. Biochim Biophys Acta 1971; 236: 17-28
    CrossrefPubMedGoogle Scholar
  • 21 Isoelectric Focusing. Principles and Methods. Pharmacia Fine Chemicals Uppsala: 1982
    Google Scholar
  • 22 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci (USA) 1979; 76: 4350-4354
    CrossrefPubMedGoogle Scholar
  • 23 Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med 1978; 91: 83-95
    PubMedGoogle Scholar
  • 24 Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982; 69: 462-468
    CrossrefPubMedGoogle Scholar
  • 25 Van der GraafF, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-158
    CrossrefPubMedGoogle Scholar
  • 26 Revak SD, Cochrane CG, Johnston AR, Hugli TE. Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest 1974; 54: 619-627
    CrossrefPubMedGoogle Scholar
  • 27 Lämmle B, Berrettini M, Schwarz HP, Heeb MJ, Griffin JH. Quantitative immunoblotting assay of blood coagulation factor XII. Thromb Res 1986; 41: 747-759
    CrossrefPubMedGoogle Scholar
  • 28 Van der GraafF, Tans G, Bouma BN, Griffin JH. Isolation and functional properties of the heavy and light chains of human plasma kallikrein. J Biol Chem 1982; 257: 14300-14305
    PubMedGoogle Scholar
  • 29 Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci (USA) 1976; 73: 2554-2558
    CrossrefPubMedGoogle Scholar
  • 30 Bouma BN, Griffin JH. Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 1977; 252: 6432-6437
    PubMedGoogle Scholar
  • 31 Pixley RA, Schapira M, Colman RW. The regulation of human factor Xlla by plasma proteinase inhibitors. J Biol Chem 1985; 260: 1723-1729
    PubMedGoogle Scholar
  • 32 Scott CF, Silver LD, Purdon AD, Colman RW. Cleavage of human high molecular weight kininogen by factor XIa in vitro. J Biol Chem 1985; 260: 10856-10863
    PubMedGoogle Scholar
  • 33 Spragg J, Kaplan AP, Austen KF. The use of isoelectric focusing to study components of the human plasma kinin-forming system. Ann NY Acad Sci 1973; 209: 372-385
    CrossrefPubMedGoogle Scholar